A citation-based method for searching scientific literature

T Forst, R Guthrie, R Goldenberg, J Yee, U Vijapurkar, G Meininger, P Stein. Diabetes Obes Metab 2014
Times Cited: 193



H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
Times Cited: 422




List of shared articles



Times cited

Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes.
Jamie L Benham, Jane E Booth, Ronald J Sigal, Stella S Daskalopoulou, Alexander A Leung, Doreen M Rabi. Int J Cardiol Heart Vasc 2021
2

Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis.
E G Dorsey-Treviño, J G González-González, N Alvarez-Villalobos, V González-Nava, B M Contreras-Garza, A Díaz González-Colmenero, G Rodríguez-Tamez, F J Barrera-Flores, A M Farrell, V M Montori,[...]. J Endocrinol Invest 2020
8


Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease.
Kazuomi Kario, Keith C Ferdinand, James H O'Keefe. Prog Cardiovasc Dis 2020
16

Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk.
Francesco Giorgino, Jiten Vora, Peter Fenici, Anna Solini. Cardiovasc Diabetol 2020
9

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors.
Fan Yang, Ran Meng, Da-Long Zhu. Chronic Dis Transl Med 2020
0

Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Chaojie Feng, Minxiang Wu, Zhengyue Chen, Xiongwei Yu, Zhenyu Nie, Yu Zhao, Beiyan Bao. Int Urol Nephrol 2019
6

Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control.
Manash Pratim Baruah, B M Makkar, Vikrant B Ghatnatti, Kaushik Mandal. Indian J Endocrinol Metab 2019
5

The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection.
Charalampos Loutradis, Eirini Papadopoulou, Marietta Theodorakopoulou, Asterios Karagiannis, Pantelis Sarafidis. Future Med Chem 2019
14

SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects.
Anastasios Tentolouris, Panayotis Vlachakis, Evangelia Tzeravini, Ioanna Eleftheriadou, Nikolaos Tentolouris. Int J Environ Res Public Health 2019
46

Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure.
Konstantinos Imprialos, Konstantinos Stavropoulos, Vasilios Papademetriou. Heart Fail Clin 2019
0


Systematic Review of Efficacy and Safety of Newer Antidiabetic Drugs Approved from 2013 to 2017 in Controlling HbA1c in Diabetes Patients.
Sivanandy Palanisamy, Emily Lau Hie Yien, Ling Wen Shi, Low Yi Si, See Hui Qi, Laura Soon Cheau Ling, Teng Wai Lun, Yap Nee Chen. Pharmacy (Basel) 2018
6


Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.
Vasilios Tsimihodimos, Theodosios D Filippatos, Moses S Elisaf. Expert Opin Drug Metab Toxicol 2017
14

Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis.
Maria Lorenzi, Uffe Jon Ploug, Jakob Langer, Rasmus Skovgaard, Michael Zoratti, Jeroen Jansen. Diabetes Ther 2017
12

An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.
Joseph A Messana, Stanley S Schwartz, Raymond R Townsend. Vasc Health Risk Manag 2017
5

Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus.
Hala Ahmadieh, Nisrine Ghazal, Sami T Azar. Diabetes Metab Syndr Obes 2017
6




The effect of SGLT2 inhibitors on cardiovascular events and renal function.
Konstantinos P Imprialos, Konstantinos Stavropoulos, Michael Doumas, Asterios Karagiannis, Vasilios G Athyros. Expert Rev Clin Pharmacol 2017
7